Bio-IT World News Bulletin describes how Pfizer has adopted D360 as Pfizer’s core research platform.
ST. LOUIS, MO – 2013年7月29日 Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that Pfizer selected Certara’s D360™ software solution for scientific data access and analysis after a thorough evaluation and comparison with several other systems.
“In 2010, Pfizer formed a partnership with Certara, an informatics company based in St. Louis, MO, to adopt Certara’s software system D360 as Pfizer’s core research platform. After a steady, months-long migration of users, Pfizer will complete its transition to D360 this year, replacing an internally-developed platform, RGate, in use since 2005. When the rollout is complete, D360 will be deployed to nearly 2,000 researchers across twelve global sites, making Pfizer the largest client to adopt D360 to date. “D360 is the core gateway for us in accessing information,” said Matteo di Tommaso, VP of Research Business Technology at Pfizer.”Read More on Bio-IT World
Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives.
Diana O’Rourke, 314-951-3310
Director of Marketing